LQDA Targets $1B 2027 Revenue; Risks Remain High

What happened

Liquidia management stated on the Q2 earnings call that it targets more than $1 billion in net revenues by 2027, driven by YUTREPIA market share gains and expansion of its inhaled-treprostinil portfolio. This target represents a significant ramp from the $51.7 million in YUTREPIA product sales recorded in Q3 2025 and the $54.3 million total revenue for that quarter. However, the company still faces substantial risks including going-concern warnings, negative free cash flow, and ongoing litigation with United Therapeutics that could restrict YUTREPIA commercialization. The stock trades at extreme multiples (P/B ~138x, negative EV/EBITDA) and has risen over 220% in the past year, suggesting the market is already pricing in a very optimistic scenario. While the revenue target may indicate management confidence, it remains highly uncertain given legal and competitive headwinds.

Implication

Unless the company demonstrates sustained free cash flow generation and favorable resolution of legal disputes, the risk-reward remains unattractive; the $1B target is plausible only under ideal conditions, and the stock's extreme valuation suggests potential for significant downside.

Thesis delta

The new revenue target does not alter the fundamental risk profile: the company still relies on a single product facing entrenched competition and active litigation. While the target is more specific than previous guidance, it remains aspirational and does not mitigate going-concern or financing risks. Therefore, the thesis remains tilted toward a potential sell or underweight stance.